A 28-year-old woman with a 3-year history of generalized tonic-clonic seizures presents to the neurology clinic. She has been seizure-free for 6 months on levetiracetam 1000 mg twice daily. MRI brain and EEG are normal. She is planning pregnancy within the next 6 months and asks about her antiepileptic drug (AED). What is the most appropriate next step in management?

Explanation

## Management of AED in Pregnancy Planning **Key Point:** Levetiracetam is one of the safest AEDs in pregnancy (Category C) with minimal teratogenic risk, and a seizure-free patient should continue effective therapy with appropriate counseling and supplementation. ### Rationale for Correct Answer **High-Yield:** The principle of seizure management in women of childbearing potential is: **continue effective seizure control** rather than discontinue therapy, as uncontrolled seizures pose greater risk to mother and fetus than most AEDs. **Clinical Pearl:** Levetiracetam has: - No enzyme induction (unlike phenytoin, carbamazepine, phenobarbital) - Minimal protein binding - No significant drug interactions with oral contraceptives - Lowest teratogenic risk among commonly used AEDs - No known association with major fetal malformations **Key Point:** Folic acid supplementation (5 mg daily) should be given to all women on AEDs planning pregnancy, as enzyme-inducing AEDs increase folate metabolism and increase neural tube defect risk. ### Comparison of AED Safety in Pregnancy | AED | Teratogenic Risk | Recommendation | Key Issue | |-----|------------------|-----------------|----------| | **Levetiracetam** | Very low | **First-line in pregnancy** | Safe; minimal interactions | | Lamotrigine | Low | Acceptable | Levels ↓ in pregnancy; may need dose ↑ | | Lacosamide | Low | Acceptable | Newer; limited data | | **Valproate** | **High (10–20%)** | **Avoid if possible** | Spina bifida, developmental delay | | Phenytoin | Moderate–High | Avoid | Fetal hydantoin syndrome | | Carbamazepine | Moderate | Avoid | Spina bifida risk; enzyme inducer | | Phenobarbital | High | Avoid | Enzyme inducer; teratogenic | **Warning:** Valproate is contraindicated in pregnancy planning due to high risk of neural tube defects (1–2%) and neurodevelopmental impairment. Switching TO valproate is absolutely wrong. ### Management Algorithm ```mermaid flowchart TD A[Woman with epilepsy planning pregnancy]:::outcome --> B{Currently seizure-free on AED?}:::decision B -->|Yes| C[Continue current AED if low teratogenic risk]:::action B -->|No| D[Optimize seizure control first]:::action C --> E[Add folic acid 5 mg daily]:::action D --> E E --> F[Counsel on seizure risk vs AED risk]:::action F --> G[Plan pregnancy with neurology + obstetrics]:::action G --> H[Monitor seizure frequency and AED levels in pregnancy]:::outcome ``` **Key Point:** Discontinuing AED in a seizure-free patient increases risk of breakthrough seizures, which carry higher maternal and fetal morbidity/mortality than continued therapy. [cite:Harrison 21e Ch 369]